findmyKOL

Amit Singal, MD

Enriched profile

Professor of Internal Medicine; Chief of Hepatology; Medical Director, Liver Tumor Program; Willis C. Maddrey, M.D. Distinguished Chair in Liver Disease; Dedman Family Scholar in Clinical Care · University of Texas Southwestern Medical Center

ORCIDNPI
Region🇺🇸 Dallas, TX · South Central · United StatesSpecialtyGastroenterologyFocusHepatocellular Carcinoma Treatment and Prognosis+4
Active KOLLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2017–2026

Amit Singal is Professor of Internal Medicine; Chief of Hepatology; Medical Director, Liver Tumor Program; Willis C. Maddrey, M.D. Distinguished Chair in Liver Disease; Dedman Family Scholar in Clinical Care at University of Texas Southwestern Medical Center. OpenAlex indexes 1,020 publications with 48,718 citations (h-index 98); ClinicalTrials.gov lists 9 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Gastroenterology profiles in the findmyKOL directory.

Data verified 17 Aug 2026

Overview

Updated 27 Aug 2026

Amit G. Singal, MD, is Professor of Internal Medicine at University of Texas Southwestern Medical Center, Division of Digestive and Liver Diseases, Department of Internal Medicine, Dallas, TX. The public record shows 1,020 publications with 48,718 citations (h-index 98), centered on Hepatocellular Carcinoma Treatment and Prognosis, Liver Disease Diagnosis and Treatment, Liver Disease and Transplantation. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 26 companies, 10 NIH-funded awards (2017–2026).

  • Most recent indexed publication: 2026 · Liver international
  • Top research focus: Hepatocellular Carcinoma Treatment and Prognosis
  • 9 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 26 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Hepatobiliary Cancer6 trialsLiver Neoplasms3 trialsColorectal Cancer2 trialsRectal Neoplasms2 trialsLiver Cirrhosis2 trialsViral Hepatitis (B/C)1 trialHepatitis B1 trial

Research focus

OpenAlex concept fingerprint
Hepatocellular Carcinoma Treatment and PrognosisLiver Disease Diagnosis and TreatmentLiver Disease and TransplantationHepatitis C virus researchColorectal Cancer Screening and Detection

Drugs & molecules

across trials, industry payments and publications
Tecentriqgeneric · AtezolizumabClinical trialsIndustry payments31Publications3Lenvimageneric · LenvatinibClinical trialsIndustry payments12Publications2Nexavargeneric · SorafenibClinical trialsIndustry payments4Publications1

Works with

trial sponsors and companies reporting payments
Gilead Sciences, Inc.Clinical trialsIndustry payments58AstraZeneca Pharmaceuticals LPClinical trialsIndustry payments44Bayer HealthCare Pharmaceuticals Inc.Clinical trialsIndustry payments33

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,020publications

Distinct works indexed by OpenAlex, matched via ORCID; 120 in PubMed.

48,718citations

Total citations across indexed works.

98h-index

Hirsch index (OpenAlex). i10-index 374.

Clinical & industry

trials, payments and federal funding
9clinical trials

Investigator role on registered studies.

View trials
26companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
10NIH grants · 2017–2026

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:

6 more trial records behind the reveal.Reveal →

Industry payments

Updated 27 Aug 2026

26 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    62.5%
    Proton pump inhibitor62.5%
    Pantoprazole Sodium100%
    Part D<11 patients
  • Anti-infectives

    37.5%
    Nucleoside and nucleotide reverse transcriptase inhibitors37.5%
    Vemlidy100%
    Part D<11 patients
Where care is delivered (Part B)50.4% facility · 49.6% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

10 NIH research awards on record, funded 20172026 per NIH RePORTER. The latest:

Congress activity

Updated 27 Aug 2026

28 congress contributions (2012–2025) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Nicole E. Rich185Neehar D. Parikh162Adam C. Yopp151

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/amit-singal-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • ResearchGate

    researchgate.net/profile/Amit-Singal

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net
  • X / Twitter

    x.com/docamitgs

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com

Mentions by others

where others cite or feature them
  • Other

    aasld.org/liver-fellow-network/core-series/podcast/diving-deep-hcc-amit-singal

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aasld.org
  • Other

    aasld.org/the-liver-meeting/speakers/amit-g-singal-35785

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aasld.org
  • X / Twitter

    X (Twitter) handle @docamitgs

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Chair

    ILCA (International Liver Cancer Association) 2025 Scientific Committee

    2025
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oaepublish.com
  • verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oaepublish.com
  • Associate Editor

    Clinical Gastroenterology and Hepatology

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →us.elsevierhealth.com

Awards & honors

honors on the public record
3 more awards behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution
  • Chief Medical Officer

    Curve Biosciences

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →businesswire.com
  • Faculty

    Department of Public Health, UT Southwestern Medical Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.utsouthwestern.edu

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.